Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gdue is a dietary supplement developed by Aesculapius Farmaceutici, formulated to support glycemic control and body weight management. It contains InSea2®, a proprietary, polyphenol-rich phytocomplex extracted from the brown seaweeds *Ascophyllum nodosum* and *Fucus vesiculosus*, combined with chromium picolinate. Gdue acts as a dual inhibitor of alpha-amylase and alpha-glucosidase, the primary digestive enzymes responsible for carbohydrate breakdown, thereby slowing down glucose absorption and reducing postprandial blood glucose and insulin spikes. It is primarily used as a nutritional support to improve insulin sensitivity, manage blood sugar levels, and assist in weight loss or metabolic syndrome management.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Gdue.